Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mike Ward
TikoMed founder and CEO Adam Bruce talks to Scrip during BIO-Europe Spring about how the company's IBsolvMIR platform has the potential to improve the viability of cells prior to transplantation.
Roel Schaapveld, CEO of InteRNA, chats with Scrip on the sidelines of the 2018 BIO-Europe Spring partnering event about upcoming milestones for the company's RNA pipeline.
With six oncology assets in Phase II/III ready for outlicensing, Oncology Venture is now looking to take additional programs on board.
While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with COPD in NEJM, two clinicians in an accompanying editorial argue that the trial falls short of providing robust evidence for switching strategy.
Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4% stake worth €900,000. Since their formation, Biovertis and Morphochem have had more than $96m invested in them.
At a pre-money valuation of $2bn, BenevolentAI raises $115m to develop artificial intelligence approach that already can cut early drug development timeline by four years.